Value of red blood cell distribution width-to-platelet ratio in evaluating metabolic-associated fatty liver disease and liver cirrhosis

Yitong BAI; Lianjie LIN; Dongmei PEI

doi:10.3969/j.issn.1001-5256.2022.04.013

Volume 38 Issue 4

Apr. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(4): 805-809

PDF( 2520 KB)

Value of red blood cell distribution width-to-platelet ratio in evaluating metabolic-associated fatty liver disease and liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.04.013

a.
Department of General Medicine, Shengjing Hospital, China Medical University, Shenyang 110004, China
b.
Department of Gastroenterology, Shengjing Hospital, China Medical University, Shenyang 110004, China

Research funding:

Shenyang Science and Technology Plan Project (F14-158-9-49)

More Information

Corresponding author: PEI Dongmei, peidm@sj-hospital.org(ORCID: 0000-0002-1947-4447)
Received Date: 2021-08-30
Accepted Date: 2021-10-11
Published Date: 2022-04-20

Abstract

Abstract

Objective To investigate the clinical significance of red blood cell distribution width-to-platelet ratio (RPR index) in evaluating the severity of metabolic-associated fatty liver disease and predicting fatty liver-associated cirrhosis. Methods A total of 192 patients with metabolic-associated fatty liver disease and 210 patients with fatty liver-associated cirrhosis who were admitted to Shengjing Hospital of China Medical University from January 2019 to June 2020 were enrolled as group A and group B, respectively, and 206 individuals who underwent physical examination in our hospital during the same period of time were enrolled as control group (group C). All subjects underwent general measurement, blood cell analysis, blood biochemical test, and abdominal CT examination, and related formulas were used to calculate RPR, aspartate aminotransferase-to-platelet ratio index (APRI), and fibrosis-4 (FIB-4) index. A one-way analysis of variance was used for comparison of continuous data with homogeneity of variance between groups, and the SNK method was used for comparison between two groups; the Kruskal-Wallis H test was used for comparison of continuous data with heterogeneity of variance between groups, and the Mann-Whitney U test was used for comparison between two groups; the chi-square test was used for comparison of categorical data between groups; the receiver operating characteristic (ROC) curve was used to analyze the accuracy of the prediction of liver cirrhosis. Results There were significant differences in red blood cell distribution width-standard deviation, albumin, creatinine, body mass index, RPR, and APRI between any two groups (all P < 0.001), and there were significant differences in white blood cell count, platelet count, alanine aminotransferase, aspartate aminotransferase, direct bilirubin, blood urea nitrogen, and FIB-4 between group A and group B (all P < 0.05). There were significant differences in waist circumference and fasting blood glucose between groups A and B and between groups A and C (all P < 0.001). There was a significant difference in RPR between any two groups of the mild, moderate, and severe metabolic-associated fatty liver disease groups (all P < 0.05). In terms of diagnostic efficiency, the three noninvasive models RPR, APRI, and FIB-4 had an area under the ROC curve of 0.932, 0.815, and 0.877, respectively, in predicting fatty liver-associated cirrhosis. Conclusion There is a difference in RPR index between different stages of liver disease, and RPR index gradually increases with the aggravation of metabolic-associated fatty liver disease. RPR index has a higher value than APRI and FIB-4 in the warning of fatty liver-associated cirrhosis.
- Non-Alcoholic Fatty Liver Disease,
- Liver Fibrosis,
- Platelet Count,
- Red Blood Cell Distribution Width

FullText(HTML)

References(20)

References

[1]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[2]	XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007. 薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
[3]	LEONI S, TOVOLI F, NAPOLI, et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis[J]. World J Gastroenterol, 2018, 24(30): 3361-3373. DOI: 10.3748/wjg.v24.i30.3361.
[4]	SHIHA G, ALSWAT K, AL KHATRY M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: A consensus from the Middle East and north Africa[J]. Lancet Gastroenterol Hepatol, 2021, 6(1): 57-64. DOI: 10.1016/S2468-1253(20)30213-2.
[5]	SHIHA G, IBRAHIM A, HELMY A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: A 2016 update[J]. Hepatol Int, 2017, 11(1): 1-30. DOI: 10.1007/s12072-016-9760-3.
[6]	WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38(2): 518-526. DOI: 10.1053/jhep.2003.50346.
[7]	WANG H, WANG J, XIA J, et al. Red cell distribution width to platelet ratio predicts liver fibrosis in patients with autoimmune hepatitis[J]. Medicine (Baltimore), 2020, 99(34): e21408. DOI: 10.1097/MD.0000000000021408.
[8]	ZHU LY, LI YC, DENG LH, et al. Research advances in extrahepatic diseases associated with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37(9): 2215-2219. DOI: 10.3969/j.issn.1001-5256.2021.09.043. 朱蕗颖, 李雨晨, 邓利华, 等. 非酒精性脂肪性肝病相关肝外疾病的研究进展[J]. 临床肝胆病杂志, 2021, 37(9): 2215-2219. DOI: 10.3969/j.issn.1001-5256.2021.09.043.
[9]	MOTAMED N, RABIEE B, HEMASI GR, et al. Body roundness index and waist-to-height ratio are strongly associated with non-alcoholic fatty liver disease: A population-based study[J]. Hepat Mon, 2016, 16(9): e39575. DOI: 10.5812/hepatmon.39575.
[10]	CUI HZ, MA XM, LIU Q, et al. Influence of the interaction between abdominal obesity and hypertriglyceridemia on the development of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1314-1319. DOI: 10.3969/j.issn.1001-5256.2020.06.025. 崔皓哲, 马向明, 刘倩, 等. 腹型肥胖与甘油三酯的交互作用对非酒精性脂肪性肝病发病的影响[J]. 临床肝胆病杂志, 2020, 36(6): 1314-1319. DOI: 10.3969/j.issn.1001-5256.2020.06.025.
[11]	CETINKAYA E, SENOL K, SAYLAM B, et al. Red cell distribution width to platelet ratio: New and promising prognostic marker in acute pancreatitis[J]. World J Gastroenterol, 2014, 20(39): 14450-14454. DOI: 10.3748/wjg.v20.i39.14450.
[12]	PUSUROGLU H, CAKMAK HA, AKGUL O, et al. The prognostic value of admission red cell distribution width-to-platelet ratio in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Rev Port Cardiol, 2015, 34(10): 597-606. DOI: 10.1016/j.repc.2015.03.014.
[13]	JIANG X, WANG Y, SU Z, et al. Red blood cell distribution width to platelet ratio levels in assessment of histologic severity in patients with primary biliary cholangitis[J]. Scand J Clin Lab Invest, 2018, 78(4): 258-263. DOI: 10.1080/00365513.2018.1449011.
[14]	XIE S, CHEN X. Red blood cell distribution width-to-platelet ratio as a disease activity-associated factor in systemic lupus erythematosus[J]. Medicine (Baltimore), 2018, 97(39): e12342. DOI: 10.1097/MD.0000000000012342.
[15]	CAI Y, LIU D, CUI J, et al. Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting staging liver fibrosis in chronic liver disease patients: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2019, 98(14): e15096. DOI: 10.1097/MD.0000000000015096.
[16]	SALVAGNO GL, SANCHIS-GOMAR F, PICANZA A, et al. Red blood cell distribution width: A simple parameter with multiple clinical applications[J]. Crit Rev Clin Lab Sci, 2015, 52(2): 86-105. DOI: 10.3109/10408363.2014.992064.
[17]	LI N, ZHOU H, TANG Q. Red blood cell distribution width: A novel predictive indicator for cardiovascular and cerebrovascular diseases[J]. Dis Markers, 2017, 2017: 7089493. DOI: 10.1155/2017/7089493.
[18]	LYU H, ZHU CL, HAO SY. Change and significance of red cell distribution width in patients with non-alcoholic steatohepatitis[J]. J Chin Pract Diagn Ther, 2016, 30(8): 765-766. DOI: 10.13507/j.issn.1674-3474.2016.08.013. 吕辉, 祝成亮, 郝世勇. 非酒精性脂肪性肝炎患者红细胞分布宽度变化及意义[J]. 中华实用诊断与治疗杂志, 2016, 30(8): 765-766. DOI: 10.13507/j.issn.1674-3474.2016.08.013.
[19]	LI Y, DAI ZY, HUANG JJ, et al. Differences of erythrocyte distribution width and prothrombin time in patients with different degrees of liver injury[J]. Chongqing Med, 2017, 46(36): 5074-5075. DOI: 10.3969/j.issn.1671-8348.2017.36.012. 李月, 代震宇, 黄佳佳, 等. 不同程度肝损伤患者红细胞分布宽度与凝血酶原时间的差异[J]. 重庆医学, 2017, 46(36): 5074-5075. DOI: 10.3969/j.issn.1671-8348.2017.36.012.
[20]	MALEHMIR M, PFISTER D, GALLAGE S, et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer[J]. Nat Med, 2019, 25(4): 641-655. DOI: 10.1038/s41591-019-0379-5.

Relative Articles

[1]	Shoujuan LI, Li WANG, Ming ZHOU, Bei WU, Lei WANG, Meng DUAN, Hongfan LIAO, Ruiqing HU, Zhaoxia HU, Li ZHU, Juan HU. Efficacy and safety of artificial liver support therapy with a selective plasma separator in low-platelet count patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(6): 1191-1195. doi: 10.12449/JCH240619
[2]	Jingya YIN, Bingqing YANG, Yue LI. Role of pyroptosis in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 175-180. doi: 10.3969/j.issn.1001-5256.2023.01.027
[3]	Dongna ZHAO, Qian LIU, Huijie LIANG, Haozhe CUI, Lingqun MENG, Huiliang E, Liying CAO. Effect of ideal cardiovascular health metrics on the incidence rate of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 124-128. doi: 10.3969/j.issn.1001-5256.2022.01.019
[4]	Xuelian GU, Junfeng LI, Xiaorong MAO. Research advances in nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(1): 196-200. doi: 10.3969/j.issn.1001-5256.2022.01.034
[5]	Yalan LEI, Jian BI, Jingwei MAO. Impact of nonalcoholic fatty liver disease on intestinal immune cells[J]. Journal of Clinical Hepatology, 2021, 37(11): 2667-2671. doi: 10.3969/j.issn.1001-5256.2021.11.039
[6]	Shiyan YAN, Jiangao FAN. Diagnosis and treatment of hepatocellular carcinoma associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(8): 1748-1752. doi: 10.3969/j.issn.1001-5256.2021.08.002
[7]	Na YANG, Hua HE, Tianye ZHAO, Xuerong TAO, Yanhua WU, Jing JIANG. Value of red blood cell distribution width-to-platelet ratio, platelet-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio in predicting compensated liver cirrhosis in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2021, 37(6): 1319-1325. doi: 10.3969/j.issn.1001-5256.2021.06.021
[8]	Liu Ting, Wang ChenTing, Liu MeiXiao, Liu JianFeng, Zheng ShaoXiong. Association between liver fibrosis and serum uric acid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1320-1324. doi: 10.3969/j.issn.1001-5256.2020.06.026
[9]	Luo YuXin, Guo JinBo, Zhang XiaoLan. Research advances in the role of macrophages in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(3): 680-683. doi: 10.3969/j.issn.1001-5256.2020.03.046
[10]	WANG Xin, HU YiYang, LIU Ping, FENG Qin. Association between hypertension and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2584-2588. doi: 10.3969/j.issn.1001-5256.2020.11.042
[11]	Luo Yan, Shi JunPing. Research advances in the pathogenesis of nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1217-1220. doi: 10.3969/j.issn.1001-5256.2020.06.005
[12]	Jiang Zhao, Ruan Bo. The role of liver sinusoidal endothelial cells in the progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(3): 684-686. doi: 10.3969/j.issn.1001-5256.2020.03.047
[13]	Liu SuTong, Zhao WenXia. Research advances in the pathogenesis of nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1621-1625. doi: 10.3969/j.issn.1001-5256.2019.07.043
[14]	Yang Liu, Chen XiangJin, Li BianLi, Peng Ying, Xu LiHong. Value of red blood cell distribution width,mean platelet volume,and neutrophil-lymphocyte ratio in the evaluation of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(12): 2772-2775. doi: 10.3969/j.issn.1001-5256.2019.12.026
[15]	Gui WenFang, Zhu QingJing, Yang Ling. Research advances in nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(12): 2693-2697. doi: 10.3969/j.issn.1001-5256.2018.12.040
[16]	Chen Nian, Huang WeiE, Su MingHua, Jiang JianNing. Correlation between platelet indices and liver pathological staging: an analysis of 167 patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(1): 106-109. doi: 10.3969/j.issn.1001-5256.2016.01.019
[17]	Liu XiuHong, Zhao YiMing, Li Ning, Jin BoXun, Yan HuiPing, Zhao YuanShun, Li Ang, Han Zhen, Zhang AiYing. Diagnostic values of plasma Golgi protein-73 and platelet count for different stages of HBV-related liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(9): 1469-1472. doi: 10.3969/j.issn.1001-5256.2015.09.025
[18]	Yu ZhenNing, Yang Lin, Lu JianGuo. Effect of splenectomy plus pericardial devascularization on coagulation function in patients with cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2014, 30(12): 1334-1336. doi: 10.3969/j.issn.1001-5256.2014.12.024
[19]	Jin HongHui, Ding XiaoHong. ROC curve analysis of blood platelet and hyaluronic acid levels for diagnosing cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(6): 456-458.

Supplements(0)

Cited By

Cited by

Periodical cited type(14)

1.	许岩岩. 凝血酶原时间与血小板参数检验对肝硬化患者肝损伤情况的评估作用. 临床医学研究与实践. 2024(08): 93-96 .
2.	陈大同，孙跃，梁明辉，金成，李公启，许东滨，张立平. 基于深度学习的淋巴细胞热图分析及红细胞计数预测老年原发性肝癌患者术后生存期的临床价值. 中国老年学杂志. 2024(08): 1813-1816 .
3.	张月华，马玉琳，任爱莉，张月靖. 网织红细胞血红蛋白含量在诊断单采血小板铁缺乏中的应用. 系统医学. 2024(09): 33-37 .
4.	王燚鑫，胡梦茹，赵永红，衣桂荣，陈爱荣. TyG、PLR与代谢相关脂肪性肝病合并慢性乙型肝炎患者肝纤维化的关系研究. 现代生物医学进展. 2024(14): 2694-2698+2693 .
5.	刘华柱，张欢，张献文. 失代偿期肝硬化患者门静脉血栓形成的相关因素分析及D-二聚体/血小板比值的预测价值. 临床消化病杂志. 2024(04): 270-274 .
6.	王凯，郭爱荣，王艳. PLT、IGFBP-3、ALB联合诊断对肝硬化上消化道出血的预测价值. 华夏医学. 2024(04): 145-150 .
7.	张嘉欣，韩文，葛彪，白莆菥. 肝硬化食管胃底静脉曲张无创预测的研究进展. 肝脏. 2024(08): 1005-1009 .
8.	孔钦香，盛吉芳. 慢性乙肝肝硬化患者肝性脑病不同分级与肝脏储备功能的相关性. 中国微生态学杂志. 2023(02): 190-196 .
9.	田丽，许勤华，郭旭. RPR预测感染性休克患者发生急性呼吸窘迫综合征的价值. 河南医学高等专科学校学报. 2023(01): 13-17 .
10.	于巧丽，张丽利. 非酒精性脂肪性肝炎外周血NLR、RDW、MPV变化及其意义探讨. 罕少疾病杂志. 2023(04): 65-66+81 .
11.	何宏材，苏鹏宇，侯立朝，樊海宁. 红细胞分布宽度与血小板计数比值和血小板-白蛋白-胆红素评分预测肝脏多房棘球蚴病术后并发症的列线图构建. 中国普外基础与临床杂志. 2023(07): 795-801 .
12.	张小娟，马昕. 红细胞分布宽度与血小板计数比值与慢性阻塞性肺疾病急性发作风险的相关性分析. 检验医学与临床. 2023(19): 2885-2888 .
13.	梁忆佳，李金洋，赵氲. 肝硬化患者凝血酶原时间及血小板指标检验的临床价值. 中国老年学杂志. 2023(22): 5458-5460 .
14.	王广春，曹洋. 红细胞分布宽度及其衍生物作为消化系统炎症和肿瘤疾病标志物的研究进展. 南京医科大学学报(自然科学版). 2023(12): 1764-1770 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (870) PDF downloads(93)

Value of red blood cell distribution width-to-platelet ratio in evaluating metabolic-associated fatty liver disease and liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.04.013